A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439

Trial Profile

A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Doravirine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2014 Status changed from not yet recruiting to recruiting as reported ClinicalTrial.gov record.
    • 25 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top